Plain-English translation of NCT06978088 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called combined with a medication called to treat chronic lymphocytic leukemia and small lymphocytic lymphoma — types of blood cancer — in people who have already received other treatments. Researchers want to find the safest dose of this combination and see how well it works, particularly for patients whose cancer developed resistance to a common treatment called BTK inhibitors.
Many people with this blood cancer eventually become resistant to standard treatments, leaving them with limited options. This trial exists to explore whether this medication combination could help patients whose cancer no longer responds to existing therapies, especially those with a specific genetic change that makes their disease harder to treat.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth daily for 12 cycles (each cycle is about 4 weeks). Around week 7, you would start receiving through an infusion at the clinic on specific days. Throughout the study, you would have blood tests, imaging scans, and possibly bone marrow biopsies to check how well the treatment is working. At the end of 12 cycles, doctors will assess your response; if you achieve a deep response, you may be able to stop treatment, or you may continue based on your doctor's recommendation.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States